DUBLIN, May 20, 2015 /PRNewswire/ -- Actavis plc (NYSE: ACT), a leading global pharmaceutical company, today announced that Brent Saunders, CEO and President of Actavis, will provide an overview and update of the Company's business at Bernstein's Thirty-First Annual Strategic Decisions Conference 2015 in New York City.
The presentation will take place on Thursday, May 28, 2015 at 11:00 a.m. Eastern Time at the Waldorf Astoria Hotel, New York, NY. To access a live webcast of the presentation, visit Actavis' Investor Relations Web site at http://ir.actavis.com. The webcast can also be accessed at the following URL: http://cc.talkpoint.com/bern001/052715a_ae/?entity=37_1RUMTG4.
An archived version will be available approximately one hour after the live presentation ends and can be accessed at the same locations for 90 days.
Actavis plc (NYSE: ACT), headquartered in Dublin, Ireland, is a unique, global pharmaceutical company and a leader in a new industry model – Growth Pharma. Actavis is focused on developing, manufacturing and commercializing innovative branded pharmaceuticals, high-quality generic and over-the-counter medicines and biologic products for patients around the world.
Actavis markets a portfolio of best-in-class products that provide valuable treatments for the central nervous system, eye care, medical aesthetics, gastroenterology, women's health, urology, cardiovascular and anti-infective therapeutic categories, and operates the world's third-largest global generics business, providing patients around the globe with increased access to affordable, high-quality medicines. Actavis is an industry leader in research and development, with one of the broadest development pipelines in the pharmaceutical industry and a leading position in the submission of generic product applications globally.
With commercial operations in approximately 100 countries, Actavis is committed to working with physicians, healthcare providers and patients to deliver innovative and meaningful treatments that help people around the world live longer, healthier lives.
Actavis intends to adopt a new global name – Allergan – pending shareholder approval in 2015.
For more information, visit Actavis' website at www.actavis.com.
Investors: Lisa DeFrancesco (862) 261-7152
Media: David Belian (862) 261-8141
SOURCE Actavis plc